Affiliated Companies

SPIMACO was established in the year 1986 in the Kingdom of Saudi Arabia (as a Public Joint Stock Company) . SPIMACO and its subsidiaries are engaged in medical and pharmaceutical production including manufacturing, producing, developing, marketing, selling and distributing pharmaceutical raw materials, medical and pharmaceutical solutions, production supplies and equipment in addition to producing medical consumables in addition to other Investments in many companies. SPIMACO capital amounts to SAR 1.2 billion,  of which ACDIMA owns 20.488%.    

JULPHAR was established in the year 1980 in the United Arab Emirates, as a public joint stock company, it is currently one of the largest pharmaceutical manufacturers in the Middle East and North Africa, distributing medicine in more than 40 Countries. The company has factories in the United Arab Emirates specialized in producing pills, solutions and suspensions. The company also established several factories in Ethiopia, Bangladesh and Saudi Arabia as part of its continuous global expansion strategy. JULPHAR's capital amounts to AED 1.159 Billion, of which ACDIMA owns 9.1509%.

ACDIMA Center for Bioequivalence and Pharmaceutical Studies was established in 2000 and is 100% owned by ACDIMA. It conducts bioavailability and bioequivalence studies, clinical trials, pharmacokinetic studies, pharmaceutical research, and chemical analysis of biological samples. The center has carried out bioequivalence studies for various pharmaceutical formulations for several factories and pharmaceutical companies in Arab and foreign countries. It has become an accredited center for a significant number of Arab and international health authorities, having obtained accreditation from the World Health Organization (WHO) and the Turkish Ministry of Health, as well as accreditation from the Malaysian Ministry of Health in recent years, serving as a reference center for these studies.

CAD was established in 2006 in the Kingdom of Saudi Arabia, with ACDIMA owning 25% of it. CAD Middle East Pharmaceutical Industries is a modern, multipurpose industrial facility designed based on the concept of independent manufacturing units, utilizing the latest technological systems for producing high-quality products from active pharmaceutical ingredients (APIs) in accordance with globally recognized Good Manufacturing Practices (GMP). The commercial production phase began in 2013. CAD relies on scientific research and continuous development to achieve high quality while adhering to Good Manufacturing Practices and cost-effective production of innovative and renewable active pharmaceutical ingredients for our diverse client base. The company’s paid-up capital is 200 million Saudi Riyals.

ACAI was established in 1975 as an Arab joint stock company. ACAI opened its factory in 1997 and produces antibiotic in its diffrent  forms according to the latest specifications of good pharmaceutical manufacturing. ACAI products have earned a good reputation in Iraq and its products have been registered in a number of Arab countries. The company is following the developments in the antibiotic industry and working on the manufacture of new varieties, in line with the global production and in order to qualify for the entry of international markets in the future. The company’s capital is nearly Iraqi Dinars 87.5 Billion, of which ACDIMA owns 34.06%.

The Arab Company for Drugs Limited is a Sudanese company established in 2007 with Arab investment, in collaboration with major Arab and Sudanese organizations working in the field of business development according to specific strategies. It is considered the largest company in Sudan for the production of human and veterinary medicines. AD has been designed and structured to the highest standards to comply with international laws and regulations in the pharmaceutical manufacturing field. The company’s factory is equipped with three different production lines with the latest equipment to meet the needs of Sudan and neighboring countries. The registered and paid-up capital of the company is approximately 2.185 Billion Sudanese pounds, with ACDIMA holding a 40% stake in the company's capital.

SAIPH was established in the year 1992 through joint Arab financing and is considered as one of the pioneering companies in Tunisia. It includes five factories for the production .SAIPH distributes its products in Tunisia and to several Arab and African Countries. It also  produces medicine with generic licenses and genetic medicine, and has developed the concept of handling for some local and international laboratories. SAIPH capital nearly amounted to TND 62 million, of which ACDIMA owns 64.14 %. 

TAPHCO was established in the year 2000 in Algeria, commencing commercial production in 2017 of selected drugs covering various therapeutic segments under TAPHCO trademarks. The company also does contracted productions for SPIMACO to manufacture and produce some of SPIMACO’s agreed upon drugs. TAPHCO also purchased production files from distinguished international pharmaceutical companies, while enjoying high revenues in the Algerian Market. The company’s capital is nearly DZD 1.083 Billion, of which ACDIMA owns 28.98%.  

 company is a joint-stock entity established in 2000 under the name IPharma. It began its production and marketing activities at its factory in Tangier in 2003.  The main purposes of the company include manufacturing, processing, importing, exporting, as well as distribution and wholesale sales in both domestic and international markets for all pharmaceutical products,  cosmetics, and personal hygiene products, in addition to any other products for human or veterinary medicine. The company produces liquid pharmaceuticals alongside a portfolio of solid products, including tablets and capsules. Some capsule products and other solid forms are packaged under local manufacturing agreements for various therapeutic categories. The company's capital is 567 million Moroccan Dirhams,  with ACDIMA holding a 20.01% stake in the company's capital.  

This company was established in 2018 in Ivory Coast with the aim of building a factory for the production of pharmaceutical materials and cosmetics, as well as all essential and vital supplementary products. It focuses on the purchase, sale, supply, and export of these products and medical promotion of related materials. The company’s capital is 2.5 Billion West African Francs, equivalent to 1.2 million Kuwaiti Dinars, with ACDIMA holding a 42.08% stake in the company's capital. The company is completing the construction phase of the factory building, and efforts are underway to expedite the registration of the products in preparation for their market launch. The company’s unaudited financial results for 2022 showed losses of approximately 238 million West African Francs, equivalent to 116,620 Kuwaiti Dinars, compared to approximately 271 million West African Francs, equivalent to 132,790 Kuwaiti Finars, for 2021.

The company was established in 2015 with a capital of 5 million Libyan Dinars, with ACDIMA holding a 49% stake in the company's capital. The aim of the company is to establish a factory for intravenous solutions and to produce and market all types of intravenous solutions. This aligns with ACDIMA strategic vision and goals to support the pharmaceutical industry in Libya and the Arab world, focusing on diversity in production and covering all therapeutic categories.

ِAcdivet was first established under the name Acdima comanpy and its partner on April 29, 1992, as a simple leadership company. It was then converted into a limited liability company on June 20, 2007, with a commercial registration number of 1653 and an initial capital of 10,000,000 Syrian Pounds, which was later increased to 210,000,000 Syrian Pounds. The company is headquartered in Al-Sabboura and is fully owned by ACDIMA, with a 100% ownership stake.

ACDIMA owns 43.9% of the capital of Shamra Pharma, which amounts to 164,640,000 Syrian Pounds. The company's production has been halted since June 2012 due to the prevailing conditions in Syria. The Board of Directors of ACDIMA has decided to allocate a provision for the impairment of investment for the entire investment value in this company, in accordance with generally accepted accounting standards.